Search

Your search keyword '"Milinkovic, Ana"' showing total 294 results
Start Over Author "Milinkovic, Ana"
294 results on '"Milinkovic, Ana"'

1. The association between single-nucleotide polymorphisms within type 1 interferon pathway genes and human immunodeficiency virus type 1 viral load in antiretroviral-naïve participants

Author

Mørup, Sara Bohnstedt, Leung, Preston, Reilly, Cavan, Sherman, Brad T., Chang, Weizhong, Milojevic, Maja, Milinkovic, Ana, Liappis, Angelike, Borgwardt, Line, Petoumenos, Kathy, Paredes, Roger, Mistry, Shweta S., MacPherson, Cameron R., Lundgren, Jens, Helleberg, Marie, Reekie, Joanne, and Murray, Daniel D.

Published
2024
Full Text
View/download PDF

2. Bone turnover change after randomized switch from tenofovir disoproxil to tenofovir alafenamide fumarate in men with HIV

Author

Moore, Amelia E.B., Burns, James E., Sally, Deirdre, Milinkovic, Ana, Krokos, Georgios, John, Joemon, Rookyard, Christopher, Borca, Alessandro, Pool, Erica R.M., Tostevin, Anna, Harman, Alyss, Dulnoan, Dwight S., Gilson, Richard, Arenas-Pinto, Alejandro, Cook, Gary J.R., Saunders, John, Dunn, David, Blake, Glen M., and Pett, Sarah L.

Published
2024
Full Text
View/download PDF

3. COVAC1 phase 2a expanded safety and immunogenicity study of a self-amplifying RNA vaccine against SARS-CoV-2

Author

Szubert, Alex J., Pollock, Katrina M., Cheeseman, Hannah M., Alagaratnam, Jasmini, Bern, Henry, Bird, Olivia, Boffito, Marta, Byrne, Ruth, Cole, Tom, Cosgrove, Catherine A., Faust, Saul N., Fidler, Sarah, Galiza, Eva, Hassanin, Hana, Kalyan, Mohini, Libri, Vincenzo, McFarlane, Leon R., Milinkovic, Ana, O'Hara, Jessica, Owen, David R., Owens, Daniel, Pacurar, Mihaela, Rampling, Tommy, Skene, Simon, Winston, Alan, Woolley, James, Yim, Yee Ting N., Dunn, David T., McCormack, Sheena, and Shattock, Robin J.

Published
2023
Full Text
View/download PDF

4. Cardiometabolic health in people with HIV: expert consensus review

Author

Batterham, Rachel L, primary, Bedimo, Roger J, additional, Diaz, Ricardo S, additional, Guaraldi, Giovanni, additional, Lo, Janet, additional, Martínez, Esteban, additional, McComsey, Grace A, additional, Milinkovic, Ana, additional, Naito, Toshio, additional, Noe, Sebastian, additional, O’Shea, Donal, additional, Paredes, Roger, additional, Schapiro, Jonathan M, additional, Sulkowski, Mark S, additional, Venter, François, additional, Waters, Laura, additional, Yoruk, Ilksen Ungan, additional, and Young, Benjamin, additional

Published
2024
Full Text
View/download PDF

6. Safety and immunogenicity of a self-amplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-ranging trial

Author

Adams, Kirsty, Amini, Fahimah, Atako, Nafisah B, Bakri, Amalina, Barclay, Wendy, Brodnicki, Elizabeth, Brown, Jonathan C, Byrne, Ruth, Chilvers, Rowena, Coelho, Sofia, Day, Suzanne, Desai, Monica, Dorman, Eleanor, Elliott, Tamara, Flight, Katie E, Fletcher, James, Galang, John, Gohil, Jagruti, Gupta, Aneta, Harlow, Chris, Hu, Kai, Kalyan, Mohini, Lagrue, Dominic, Liscano, Ely, Njenga, Cecilia, Polra, Krunal, Powlette, Derecia A, Randell, Paul, Rauchenberger, Mary, Redknap, Ianto, Ricamara, Maravic, Rogers, Paul, Sallah, Hadijatou, Samnuan, Karnyart, Schumacher, Michael, Shah, Zareena, Shaw, Rachel, Shaw, Thomas, Sivapatham, Stefan, Slater, Susie, Sorley, Kim, Storch, Regina, Tan, Elizabeth, Tan, Tricia, Thielemans, Lieze, Whitely, Sarah, Valentine, Charlotte, Varghese, Jeeva, Vikraman, Asha, Wilkins, Martin, Pollock, Katrina M., Cheeseman, Hannah M., Szubert, Alexander J., Libri, Vincenzo, Boffito, Marta, Owen, David, Bern, Henry, McFarlane, Leon R., O'Hara, Jessica, Lemm, Nana-Marie, McKay, Paul, Rampling, Tommy, Yim, Yee Ting N., Milinkovic, Ana, Kingsley, Cherry, Cole, Tom, Fagerbrink, Susanne, Aban, Marites, Tanaka, Maniola, Mehdipour, Savviz, Robbins, Alexander, Budd, William, Faust, Saul, Hassanin, Hana, Cosgrove, Catherine A., Winston, Alan, Fidler, Sarah, Dunn, David, McCormack, Sheena, and Shattock, Robin J.

Published
2022
Full Text
View/download PDF

7. Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: an exploratory substudy of a randomised, observer-blinded, placebo-controlled, phase 3 trial

Author

Soiza, Roy L., Brittain-Long, Robin, Scicluna, Chiara, Edwards, Carole, Mackay, Lynn, D'Allesandro, Mariella, Nicol, Amy, Norris, Karen, Mann, Sandra, Lawrence, Heather, Valentine, Ruth, Viljoen, Marianne Elizabeth, Pretswell, Carol H., Nicholls, Helen, Munsoor, Imrozia, Meyrick, Agnieszka, Kyriakidou, Christina, Iyengar, Shalini, Jamal, Arham, Richards, Nick, Price, Helen, Rowbotham, Bridie, Bird, Danielle, Smith, Karen, Littler, Olga, Fielding, Kirsty, Townsend-Rose, Anna, Miller, Karen, Davis, Jessica, Elliot-Garwood, Alison, Trottier, Lauren, Edwards, Paul, McFarland, Margaret, Osanlou, Orod, Longshaw, Laura, Stockport, Jane, Grundy, Lynne, Broad, Katharine Lucy, Regan, Karen, Storton, Kim, Ryan-Wakeling, Declan, Wilson, Brad, Munisamy, Malathy, Wright, John, Shenoy, Anil, English, Beverley, Brear, Lucy, Cicconi, Paola, Boffito, Marta, Milinkovic, Ana, Byrne, Ruth, Movahedi, Roya, Housman, Rosalie, Kara, Naveed, Brown, Ellen, Cipriani, Andrea, Attenburrow, Mary-Jane, Smith, Katharine A., Packham, Jonathan, Sparrow, Geoff, Smith, Richard, Rosier, Josephine M., Saja, Khalid, Nago, Nyasha, Camilleri, Brian, Immanuel, Anita, Hamblin, Mike, Osagie, Rawlings, Mohan, Mahalakshmi, Floyd, Hilary, Goddard, Suzanne, Mutgi, Sanjay, Evans, John, McKeon, Sean, Vilimiene, Neringa, Chicano, Rosavic, Hayre, Rachel, Pandaan, Alice, Henshall, Catherine, Serrano, Sonia, Mazzella, Andrea, Rajeswaran, Thurkka, Mathew, Moncy, Bisnauthsing, Karen, Bremner, Laura, Fok, Henry, Morselli, Franca, Cinardo, Paola, Merrick, Blair, Sowole, Lucy, Broadhead, Samantha, Palmer, Natalie, Cordle, Jessica, Goldsmith, Jaimie Wilson, Cooney, Enya, Jackson, Beth, Jayatilleke, Thilina, Cheng, Zelda, Helliwell, Toby, Chudyk, Adrian, Giemza, Rafaela, Villajin, John Lord, Yogo, Noah, Makanju, Esther, Dulawan, Pearl, Nagra, Deepak, Buazon, April, Russell, Alice, Bird, Georgie, Heer, Amardeep, Sarmiento, Rex, Sanghera, Balraj, Mullin, Melanie, Champion, Adam, Bevan, Aisling, Iqbal, Kinzah, Johnson, Alshia, Clark, Rebecca, Shaw, Sarah, Shaw, Steven, Chalk, Amanda, Lovatt, Martin, Lillicrap, Caroline, Parker, Angela, Hansel, Jan, Wong, Zhi, Gan, Galvin, Tuma, Eyad, Minton, Jane, Murira, Jennifer, Saman, Razan, Hall, Alistair, Holliday, Kyra, Khan, Zara, Calderwood, James, Twigg, George, Baker, Helena, Corrigan, Julie, Houseman, Katy, Raguvanshi, Subhra, Heining, Dominic, Weddell, Jake, Glaves, Liz, Thompson, Kim, Davies, Francis, Lambley Burke, Ruth, Thomson, Emma C., Saralaya, Dinesh, Berry, Lisa, Hopewell, Nancy, Gerdes, Leigh, Pacurar, Mihaela, Faust, Saul N., Turner, Jeremy, Jeanes, Christopher, Cooper, Adele, Keshet-Price, Jocelyn, Coke, Lou, Cambell-Kelly, Melissa, Dhatariya, Ketan, Williams, Claire, Marks, Georgina, Sudbury, James, Rodolico, Lisa, Bradley, Judy, Carr, Sharon, Martin, Roisin, Madden, Angelina, Biagioni, Paul, McKenna, Sonia, Clinton, Alison, O'Kane, Maurice, Carter, Justin, Dewhurst, Matthew, Wetherill, Bill, Hoggarth, Thandiwe, Collins, Katrina Lennon, Chowdhury, Marie, Nathoo, Adil, Heinen, Anna, MacDonald, Orla, Hurducas, Claudia, Cifuentes, Liliana, Gill, Harjeevan, Gibson, Andy, West, Raha, Ewing, Jane, Blacow, Rachel, Haughney, John, MacDonald, Jonathan, Seenan, John Paul, Webb, Stewart, O'Leary, Colin, Muir, Scott, White, Beth, Ritchie, Neil, McAuley, Daniel F., Stewart, Jonathan, D'Alessandro, Mariella, Lakeman, Nicki, Purandare, Laura, Browne, Duncan, Tucker, David, Luck, Peter, Everden, Angharad, Trembath, Lisa, Visick, Michael, Morley, Nick, Reid, Laura, Chenoweth, Helen, Maclean, Kirsty, Sheridan, Ray P., Burden, Tom, Lunt, Craig Francis, Todd, Shirley, Estcourt, Stephanie, Pearce, Jasmine Marie, Wilkins, Suzanne, Love-Rouse, Cathryn, Torok-Pollok, Eva, Youle, Mike, Madge, Sara, Solomon, Danielle, Nandani, Aarti, North, Janet M., Hemat, Nargis, Newport, Rachel, Kalra, Philip A., Chukwu, Chukwuma, Wickens, Olivia, O'Loughlin, Vikki, Mistry, Hema, Harrison, Louise, Oliver, Robert, Peers, Anne-Marie, Zadik, Jess, Doyle, Katie, Chadwick, David R., Colling, Kerry, Wroe, Caroline, Branch, Marie, Chilvers, Alison, Essex, Sarah, Stone, Mark, San Francisco Ramos, Alberto, Beales, Emily, Bird, Olivia, Danos, Zsofia, Fofie, Hazel, Hultin, Cecilia, Ikram, Sabina, Mabesa, Fran, Mescall, Aoife, Pereira, Josyanne, Pearce, Jennifer, Sutton, Natalina, Snashall, Emma, Baxter, David Neil, Bennett, Sara, Suggitt, Debbie, Hughes, Kerry, Woodyatt, Wiesia, Beacon, Lynsey, Kent, Alissa, Cooper, Chris, Rudic, Milan, Tunstall, Simon, Jackson, Matthew, Hombersley, Claire, Moore, Patrick, Cutts, Rebecca, Higham, Andrew, Bukhari, Marwan, Elnaggar, Mohamed, Glover, Michelle, Richardson, Fiona, Dent, Alexandra, Mirza, Shahzeb, Ark, Rajiv, Han, Jennie, Hope, Suzy V., Mitchelmore, Philip J., Osanlou, Rostam, Freedman, Andrew, Cooper, Alison, Burton, Katherine, Katechia, Kashyap, Barrett, Michael, Salkeld, Jo, Hill, Natalie, Lee, Nathaniel, Perkins, Jon, Fox, Polly, Toback, Seth, Galiza, Eva, Cosgrove, Catherine, Galloway, James, Goodman, Anna L, Swift, Pauline A, Rajaram, Sankarasubramanian, Graves-Jones, Alison, Edelman, Jonathan, Burns, Fiona, Minassian, Angela M, Cho, Iksung, Kumar, Lakshmi, Plested, Joyce S, Rivers, E Joy, Robertson, Andreana, Dubovsky, Filip, Glenn, Greg, and Heath, Paul T

Published
2022
Full Text
View/download PDF

9. HIV pre-exposure prophylaxis and its implementation in the PrEP Impact Trial in England: a pragmatic health technology assessment

Author

Sullivan, Ann K, primary, Saunders, John, additional, Desai, Monica, additional, Cartier, Andrea, additional, Mitchell, Holly D, additional, Jaffer, Sajjida, additional, Ogaz, Dana, additional, Chiavenna, Chiara, additional, Charlett, Andre, additional, Diamente, Victor, additional, Golombek, Rainer, additional, Manavi, Kaveh, additional, Priestley, Cecilia, additional, Waters, Laura J, additional, Milinkovic, Ana, additional, McOwan, Alan, additional, Estcourt, Claudia, additional, Sabin, Caroline A, additional, Rodger, Alison, additional, Gold, Deborah, additional, Gazzard, Brian G, additional, McCormack, Sheena, additional, and Gill, O Noel, additional

Published
2023
Full Text
View/download PDF

10. Real world utilisation of doravirine among people living with human immunodeficiency virus in England (DRIVE-REAL)

Author

O’Halloran, Charlotte, primary, Gilleece, Yvonne, additional, Leung, Suki, additional, Canuto, Veronica, additional, McAlpine, Connor, additional, Ross, Sophie, additional, Norcross, Claire, additional, Gaffney, Stuart, additional, Siani, Nipur, additional, Hickey, William, additional, Moore, Adam, additional, Rajkovic-Hooley, Olivera, additional, and Milinkovic, Ana, additional

Published
2023
Full Text
View/download PDF

13. Hepatic steatosis in people older and younger than fifty who are living with HIV and HIV‐negative controls: A cross‐sectional study nested within the POPPY cohort.

Author

Arenas‐Pinto, Alejandro, Bakewell, Nicholas, Milinkovic, Ana, Williams, Ian, Vera, Jaime, Post, Frank A., Anderson, Jane, Beynon, Michelle, O'Brien, Alastair, Doyle, Nicki, Gilson, Richard, Pett, Sarah L., Winston, Alan, and Sabin, Caroline A.

Subjects
HIV-positive persons, KRUSKAL-Wallis Test, ULTRASONIC imaging, CONFIDENCE intervals, FATTY liver, CROSS-sectional method, FISHER exact test, RISK assessment, COMPARATIVE studies, WAIST-hip ratio, RESEARCH funding, CHI-squared test, DESCRIPTIVE statistics, LOGISTIC regression analysis, ODDS ratio, DISEASE risk factors, ADULTS, MIDDLE age
Abstract

Background: Hepatic steatosis is a major cause of chronic liver disease associated with several negative health outcomes. We compared the prevalence of and factors associated with steatosis in people living with and without HIV. Methods: Older (>50 years) and younger (<50 years) people with HIV and older HIV‐negative controls (>50 years) underwent liver transient elastography examination with controlled attenuation parameter (steatosis ≥238 dB/m, moderate/severe steatosis ≥280 dB/m, liver fibrosis ≥7.1 kPa). We compared groups using logistic regression/Chi‐squared/Fisher's exact/Kruskal–Wallis tests. Results: In total, 317 participants (109 older people with HIV; 101 younger people with HIV; 107 HIV‐negative controls) were predominantly white (86%) and male (76%), and 21% were living with obesity (body mass index ≥30 kg/m2). Most (97%) people with HIV had undetectable HIV RNA. The prevalence of fibrosis was 8.4%, 3.0%, and 6.5% in the three groups, respectively (p = 0.26). Fibrosis was predominately (>65%) mild. The prevalence of steatosis was the same in older people with HIV (66.4%) and controls (66.4%) but lower in younger people with HIV (37.4%; p < 0.001). After adjustment, younger people with HIV were less likely to have steatosis (odds ratio [OR] 0.26; 95% confidence interval [CI] 0.14–0.52) than controls, but male sex (OR 2.45; 95% CI 1.20–4.50) and high waist‐to‐hip ratio (OR 3.04; 95% CI 1.74–5.33) were associated with an increased odds of steatosis. We found no association between steatosis and HIV‐related variables. Conclusions: The prevalence of hepatic steatosis and fibrosis was similar between older participants regardless of HIV status. Age, sex, and abdominal obesity, but not HIV‐related variables, were associated with steatosis. Interventions for controlling obesity should be integrated into routine HIV care. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

16. Limited Weight Impact After Switching From Boosted Protease Inhibitors to Dolutegravir in Persons With Human Immunodeficiency Virus With High Cardiovascular Risk: A Post Hoc Analysis of the 96-Week NEAT-022 Randomized Trial

Author

Waters, Laura, Assoumou, Lambert, González-Cordón, Ana, Rusconi, Stefano, Domingo, Pere, Gompels, Mark, de Wit, Stephane, Raffi, François, Stephan, Christoph, Masiá, Mar, Rockstroh, Jürgen, Katlama, Christine, Behrens, Georg M N, Moyle, Graeme, Johnson, Margaret, Fox, Julie, Stellbrink, Hans-Jürgen, Guaraldi, Giovanni, Florence, Eric, Esser, Stefan, Gatell, José M, Pozniak, Anton, Martínez, Esteban, Vandekerckhove, Linos, Caluwé, Els, Necsoi, Coca, Frankenhuijsen, Maartje Van, Allavena, Clotilde, Reliquet, Véronique, Boutoille, David, Cavellec, Morane, André-Garnier, Elisabeth, Rodallec, Audrey, Tourneau, Thierry Le, Connault, Jérôme, Molina, Jean-Michel, Ferret, Samuel, Previlon, Miresta, Yazdanpanah, Yazdan, Landman, Roland, Joly, Véronique, Pinto, Adriana, Caby, Fabienne, Ktorza, Nadine, Schneider, Luminita, Wolf, Timo, Schüttfort, Gundolf, Wasmuth, Jan-Christian, Schwarze-Zander, Carolynne, Boesecke, Christoph, Hoffmann, Christian, Sabranski, Michael, Esser, Stephan, Jablonka, Robert, Wiehler, Heidi, Stoll, Matthias, Ahrenstorf, Gerrit, Nardini, Giulia, Beghetto, Barbara, Montforte, Antonella D’Arminio, Bini, Teresa, Cogliandro, Viola, Di Pietro, Massimo, Fusco, Francesco Maria, Galli, Massimo, Giacomelli, Andrea, Meraviglia, Paola, Torres, Berta, Mateo, Gracia, Gutierrez, Mar, Portilla, Joaquin, Merino, Esperanza, Reus, Sergio, Boix, Vicente, Gutiérrez, Félix, Padilla, Sergio, Clotet, Bonaventura, Negredo, Eugenia, Bonjoch, Anna, Casado, José L, Bañón-Escandell, Sara, Saban, Jose, Duque, Africa, Podzamczer, Daniel, Saumoy, Maria, Acerete, Laura, Gonzalez-Garcia, Juan, Bernardino, José Ignacio, Arribas, José Ramón, Hontañón, Victor, Pagani, Nicole, Bracchi, Margherita, Vera, Jaime, Clarke, Amanda, Adams, Tanya, Richardson, Celia, Winston, Alan, Mora-Peris, Borja, Mullaney, Scott, Esteban, Nahum de, Milinkovic, Ana, Pett, Sarah, Tiraboschi, Juan Manuel, Youle, Mike, Orkin, Chloe, Rackstraw, Simon, Hand, James, Jennings, Louise, Nicholls, Jane, and Johnston, Sarah

Subjects
Microbiology (medical), Infectious Diseases, Medizin
Abstract

BackgroundIn the NEAT022 trial, virologically suppressed persons with human immunodeficiency virus (HIV) at high cardiovascular risk switching from protease inhibitors to dolutegravir either immediately (DTG-I) or after 48 weeks (DTG-D) showed noninferior virological suppression and significant lipid and cardiovascular disease risk reductions on switching to dolutegravir relative to continuing protease inhibitors.MethodsIn post hoc analysis, major endpoints were 48-week and 96-week weight and body mass index (BMI) changes. Factors associated with weight/BMI changes within the first 48 weeks of DTG exposure, proportion of participants by category of percentage weight change, proportions of BMI categories over time, and impact on metabolic outcomes were also assessed.ResultsBetween May 2014 and November 2015, 204 (DTG-I) and 208 (DTG-D) participants were included. Weight significantly increased (mean, +0.810 kg DTG-I arm, and +0.979 kg DTG-D arm) in the first 48 weeks postswitch, but remained stable from 48 to 96 weeks in DTG-I arm. Switching from darunavir, White race, total to high-density lipoprotein cholesterol ratio ConclusionsSwitching from protease inhibitors to dolutegravir in persons with HIV with high cardiovascular risk led to modest weight gain limited to the first 48 weeks, which involved preferentially normal-weight or underweight persons and was not associated with negative metabolic outcomes.Clinical Trials RegistrationNCT02098837 and EudraCT 2013-003704-39.

Published
2022

18. Real world utilisation of doravirine among people living with human immunodeficiency virus in England (DRIVE-REAL)

Author

O’Halloran, Charlotte, Gilleece, Yvonne, Leung, Suki, Canuto, Veronica, McAlpine, Connor, Ross, Sophie, Norcross, Claire, Gaffney, Stuart, Siani, Nipur, Hickey, William, Moore, Adam, Rajkovic-Hooley, Olivera, and Milinkovic, Ana

Abstract

Background Doravirine is a non-nucleoside reverse transcriptase inhibitor recommended for the treatment of virologically suppressed and treatment naïve people living with HIV. The DRIVE-REAL study aimed to describe the characteristics, treatment patterns, and virological outcomes of doravirine users in a real-world cohort in the UK.Methods A retrospective, observational, multi-centre chart review was conducted for 300 adults living with HIV initiating doravirine-containing antiretroviral therapy.Results At baseline 83% of individuals were male, 45% aged ≥50 years, 65% white ethnicity. Median time since HIV diagnosis was 12 years. 96% were antiretroviral therapy-experienced, 87% had a HIV viral load <50 copies/ml, and 15% had resistance to at least one antiretroviral drug. 66% had comorbidities, most commonly depression (26%), and 70% were taking at least one co-medication. At six months, 94% (n= 283/300) were still receiving doravirine. Viral load data were available for n= 266/300 individuals and 95% (n= 253/266) had viral load <50 copies/ml.Conclusions Individuals initiating doravirine in this cohort are predominantly treatment-experienced white middle-aged males, with a high frequency of comorbidities and co-medication. The majority of individuals at 6 months remained on doravirine and maintained or achieved HIV viral suppression. This study provides epidemiologic characteristics that can inform clinical care and subsequent hypothesis-testing studies.

Published
2024
Full Text
View/download PDF

25. Changes in body mass index and clinical outcomes after initiation of contemporary antiretroviral regimens

Author

Bannister, Wendy P., primary, Mast, T. Christopher, additional, de Wit, Stéphane, additional, Gerstoft, Jan, additional, Wiese, Lothar, additional, Milinkovic, Ana, additional, Hadziosmanovic, Vesna, additional, Clarke, Amanda, additional, Rasmussen, Line D., additional, Lacombe, Karine, additional, Schommers, Philipp, additional, Staub, Thérèse, additional, Zagalo, Alexandra, additional, Portu, Joseba J., additional, Tau, Luba, additional, Calmy, Alexandra, additional, Cavassini, Matthias, additional, Gisinger, Martin, additional, Borodulina, Elena, additional, Mocroft, Amanda, additional, Reekie, Joanne, additional, and Peters, Lars, additional

Published
2022
Full Text
View/download PDF

30. Safety and immunogenicity of a self-amplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-ranging trial

Author

Pollock, Katrina M., primary, Cheeseman, Hannah M., additional, Szubert, Alexander J., additional, Libri, Vincenzo, additional, Boffito, Marta, additional, Owen, David, additional, Bern, Henry, additional, McFarlane, Leon R., additional, O'Hara, Jessica, additional, Lemm, Nana-Marie, additional, McKay, Paul, additional, Rampling, Tommy, additional, Yim, Yee Ting N., additional, Milinkovic, Ana, additional, Kingsley, Cherry, additional, Cole, Tom, additional, Fagerbrink, Susanne, additional, Aban, Marites, additional, Tanaka, Maniola, additional, Mehdipour, Savviz, additional, Robbins, Alexander, additional, Budd, William, additional, Faust, Saul, additional, Hassanin, Hana, additional, Cosgrove, Catherine A., additional, Winston, Alan, additional, Fidler, Sarah, additional, Dunn, David, additional, McCormack, Sheena, additional, Shattock, Robin J., additional, Adams, Kirsty, additional, Amini, Fahimah, additional, Atako, Nafisah B, additional, Bakri, Amalina, additional, Barclay, Wendy, additional, Brodnicki, Elizabeth, additional, Brown, Jonathan C, additional, Byrne, Ruth, additional, Chilvers, Rowena, additional, Coelho, Sofia, additional, Day, Suzanne, additional, Desai, Monica, additional, Dorman, Eleanor, additional, Elliott, Tamara, additional, Flight, Katie E, additional, Fletcher, James, additional, Galang, John, additional, Gohil, Jagruti, additional, Gupta, Aneta, additional, Harlow, Chris, additional, Hu, Kai, additional, Kalyan, Mohini, additional, Lagrue, Dominic, additional, Liscano, Ely, additional, Njenga, Cecilia, additional, Polra, Krunal, additional, Powlette, Derecia A, additional, Randell, Paul, additional, Rauchenberger, Mary, additional, Redknap, Ianto, additional, Ricamara, Maravic, additional, Rogers, Paul, additional, Sallah, Hadijatou, additional, Samnuan, Karnyart, additional, Schumacher, Michael, additional, Shah, Zareena, additional, Shaw, Rachel, additional, Shaw, Thomas, additional, Sivapatham, Stefan, additional, Slater, Susie, additional, Sorley, Kim, additional, Storch, Regina, additional, Tan, Elizabeth, additional, Tan, Tricia, additional, Thielemans, Lieze, additional, Whitely, Sarah, additional, Valentine, Charlotte, additional, Varghese, Jeeva, additional, Vikraman, Asha, additional, and Wilkins, Martin, additional

Published
2022
Full Text
View/download PDF

31. Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: an exploratory substudy of a randomised, observer-blinded, placebo-controlled, phase 3 trial

Author

Toback, Seth, primary, Galiza, Eva, additional, Cosgrove, Catherine, additional, Galloway, James, additional, Goodman, Anna L, additional, Swift, Pauline A, additional, Rajaram, Sankarasubramanian, additional, Graves-Jones, Alison, additional, Edelman, Jonathan, additional, Burns, Fiona, additional, Minassian, Angela M, additional, Cho, Iksung, additional, Kumar, Lakshmi, additional, Plested, Joyce S, additional, Rivers, E Joy, additional, Robertson, Andreana, additional, Dubovsky, Filip, additional, Glenn, Greg, additional, Heath, Paul T, additional, Soiza, Roy L., additional, Brittain-Long, Robin, additional, Scicluna, Chiara, additional, Edwards, Carole, additional, Mackay, Lynn, additional, D'Allesandro, Mariella, additional, Nicol, Amy, additional, Norris, Karen, additional, Mann, Sandra, additional, Lawrence, Heather, additional, Valentine, Ruth, additional, Viljoen, Marianne Elizabeth, additional, Pretswell, Carol H., additional, Nicholls, Helen, additional, Munsoor, Imrozia, additional, Meyrick, Agnieszka, additional, Kyriakidou, Christina, additional, Iyengar, Shalini, additional, Jamal, Arham, additional, Richards, Nick, additional, Price, Helen, additional, Rowbotham, Bridie, additional, Bird, Danielle, additional, Smith, Karen, additional, Littler, Olga, additional, Fielding, Kirsty, additional, Townsend-Rose, Anna, additional, Miller, Karen, additional, Davis, Jessica, additional, Elliot-Garwood, Alison, additional, Trottier, Lauren, additional, Edwards, Paul, additional, McFarland, Margaret, additional, Osanlou, Orod, additional, Longshaw, Laura, additional, Stockport, Jane, additional, Grundy, Lynne, additional, Broad, Katharine Lucy, additional, Regan, Karen, additional, Storton, Kim, additional, Ryan-Wakeling, Declan, additional, Wilson, Brad, additional, Munisamy, Malathy, additional, Wright, John, additional, Shenoy, Anil, additional, English, Beverley, additional, Brear, Lucy, additional, Cicconi, Paola, additional, Boffito, Marta, additional, Milinkovic, Ana, additional, Byrne, Ruth, additional, Movahedi, Roya, additional, Housman, Rosalie, additional, Kara, Naveed, additional, Brown, Ellen, additional, Cipriani, Andrea, additional, Attenburrow, Mary-Jane, additional, Smith, Katharine A., additional, Packham, Jonathan, additional, Sparrow, Geoff, additional, Smith, Richard, additional, Rosier, Josephine M., additional, Saja, Khalid, additional, Nago, Nyasha, additional, Camilleri, Brian, additional, Immanuel, Anita, additional, Hamblin, Mike, additional, Osagie, Rawlings, additional, Mohan, Mahalakshmi, additional, Floyd, Hilary, additional, Goddard, Suzanne, additional, Mutgi, Sanjay, additional, Evans, John, additional, McKeon, Sean, additional, Vilimiene, Neringa, additional, Chicano, Rosavic, additional, Hayre, Rachel, additional, Pandaan, Alice, additional, Henshall, Catherine, additional, Serrano, Sonia, additional, Mazzella, Andrea, additional, Rajeswaran, Thurkka, additional, Mathew, Moncy, additional, Bisnauthsing, Karen, additional, Bremner, Laura, additional, Fok, Henry, additional, Morselli, Franca, additional, Cinardo, Paola, additional, Merrick, Blair, additional, Sowole, Lucy, additional, Broadhead, Samantha, additional, Palmer, Natalie, additional, Cordle, Jessica, additional, Goldsmith, Jaimie Wilson, additional, Cooney, Enya, additional, Jackson, Beth, additional, Jayatilleke, Thilina, additional, Cheng, Zelda, additional, Helliwell, Toby, additional, Chudyk, Adrian, additional, Giemza, Rafaela, additional, Villajin, John Lord, additional, Yogo, Noah, additional, Makanju, Esther, additional, Dulawan, Pearl, additional, Nagra, Deepak, additional, Buazon, April, additional, Russell, Alice, additional, Bird, Georgie, additional, Heer, Amardeep, additional, Sarmiento, Rex, additional, Sanghera, Balraj, additional, Mullin, Melanie, additional, Champion, Adam, additional, Bevan, Aisling, additional, Iqbal, Kinzah, additional, Johnson, Alshia, additional, Clark, Rebecca, additional, Shaw, Sarah, additional, Shaw, Steven, additional, Chalk, Amanda, additional, Lovatt, Martin, additional, Lillicrap, Caroline, additional, Parker, Angela, additional, Hansel, Jan, additional, Wong, Zhi, additional, Gan, Galvin, additional, Tuma, Eyad, additional, Minton, Jane, additional, Murira, Jennifer, additional, Saman, Razan, additional, Hall, Alistair, additional, Holliday, Kyra, additional, Khan, Zara, additional, Calderwood, James, additional, Twigg, George, additional, Baker, Helena, additional, Corrigan, Julie, additional, Houseman, Katy, additional, Raguvanshi, Subhra, additional, Heining, Dominic, additional, Weddell, Jake, additional, Glaves, Liz, additional, Thompson, Kim, additional, Davies, Francis, additional, Lambley Burke, Ruth, additional, Thomson, Emma C., additional, Saralaya, Dinesh, additional, Berry, Lisa, additional, Hopewell, Nancy, additional, Gerdes, Leigh, additional, Pacurar, Mihaela, additional, Faust, Saul N., additional, Turner, Jeremy, additional, Jeanes, Christopher, additional, Cooper, Adele, additional, Keshet-Price, Jocelyn, additional, Coke, Lou, additional, Cambell-Kelly, Melissa, additional, Dhatariya, Ketan, additional, Williams, Claire, additional, Marks, Georgina, additional, Sudbury, James, additional, Rodolico, Lisa, additional, Bradley, Judy, additional, Carr, Sharon, additional, Martin, Roisin, additional, Madden, Angelina, additional, Biagioni, Paul, additional, McKenna, Sonia, additional, Clinton, Alison, additional, O'Kane, Maurice, additional, Carter, Justin, additional, Dewhurst, Matthew, additional, Wetherill, Bill, additional, Hoggarth, Thandiwe, additional, Collins, Katrina Lennon, additional, Chowdhury, Marie, additional, Nathoo, Adil, additional, Heinen, Anna, additional, MacDonald, Orla, additional, Hurducas, Claudia, additional, Cifuentes, Liliana, additional, Gill, Harjeevan, additional, Gibson, Andy, additional, West, Raha, additional, Ewing, Jane, additional, Blacow, Rachel, additional, Haughney, John, additional, MacDonald, Jonathan, additional, Seenan, John Paul, additional, Webb, Stewart, additional, O'Leary, Colin, additional, Muir, Scott, additional, White, Beth, additional, Ritchie, Neil, additional, McAuley, Daniel F., additional, Stewart, Jonathan, additional, D'Alessandro, Mariella, additional, Lakeman, Nicki, additional, Purandare, Laura, additional, Browne, Duncan, additional, Tucker, David, additional, Luck, Peter, additional, Everden, Angharad, additional, Trembath, Lisa, additional, Visick, Michael, additional, Morley, Nick, additional, Reid, Laura, additional, Chenoweth, Helen, additional, Maclean, Kirsty, additional, Sheridan, Ray P., additional, Burden, Tom, additional, Lunt, Craig Francis, additional, Todd, Shirley, additional, Estcourt, Stephanie, additional, Pearce, Jasmine Marie, additional, Wilkins, Suzanne, additional, Love-Rouse, Cathryn, additional, Torok-Pollok, Eva, additional, Youle, Mike, additional, Madge, Sara, additional, Solomon, Danielle, additional, Nandani, Aarti, additional, North, Janet M., additional, Hemat, Nargis, additional, Newport, Rachel, additional, Kalra, Philip A., additional, Chukwu, Chukwuma, additional, Wickens, Olivia, additional, O'Loughlin, Vikki, additional, Mistry, Hema, additional, Harrison, Louise, additional, Oliver, Robert, additional, Peers, Anne-Marie, additional, Zadik, Jess, additional, Doyle, Katie, additional, Chadwick, David R., additional, Colling, Kerry, additional, Wroe, Caroline, additional, Branch, Marie, additional, Chilvers, Alison, additional, Essex, Sarah, additional, Stone, Mark, additional, San Francisco Ramos, Alberto, additional, Beales, Emily, additional, Bird, Olivia, additional, Danos, Zsofia, additional, Fofie, Hazel, additional, Hultin, Cecilia, additional, Ikram, Sabina, additional, Mabesa, Fran, additional, Mescall, Aoife, additional, Pereira, Josyanne, additional, Pearce, Jennifer, additional, Sutton, Natalina, additional, Snashall, Emma, additional, Baxter, David Neil, additional, Bennett, Sara, additional, Suggitt, Debbie, additional, Hughes, Kerry, additional, Woodyatt, Wiesia, additional, Beacon, Lynsey, additional, Kent, Alissa, additional, Cooper, Chris, additional, Rudic, Milan, additional, Tunstall, Simon, additional, Jackson, Matthew, additional, Hombersley, Claire, additional, Moore, Patrick, additional, Cutts, Rebecca, additional, Higham, Andrew, additional, Bukhari, Marwan, additional, Elnaggar, Mohamed, additional, Glover, Michelle, additional, Richardson, Fiona, additional, Dent, Alexandra, additional, Mirza, Shahzeb, additional, Ark, Rajiv, additional, Han, Jennie, additional, Hope, Suzy V., additional, Mitchelmore, Philip J., additional, Osanlou, Rostam, additional, Freedman, Andrew, additional, Cooper, Alison, additional, Burton, Katherine, additional, Katechia, Kashyap, additional, Barrett, Michael, additional, Salkeld, Jo, additional, Hill, Natalie, additional, Lee, Nathaniel, additional, Perkins, Jon, additional, and Fox, Polly, additional

Published
2022
Full Text
View/download PDF

32. COVAC1 Phase 2a Expanded Safety and Immunogenicity Study of a Self-Amplifying RNA Vaccine Against SARS-CoV-2

Author

Szubert, Alexander J., primary, Pollock, Katrina M., additional, Cheeseman, Hannah M., additional, Alagaratnam, Jasmini, additional, Bern, Henry, additional, Bird, Olivia, additional, Boffito, Marta, additional, Byrne, Ruth, additional, Cole, Tom, additional, Cosgrove, Catherine A., additional, Faust, Saul N., additional, Fidler, Sarah, additional, Galiza, Eva, additional, Hassanin, Hana, additional, Kalyan, Mohini, additional, Libri, Vincenzo, additional, McFarlane, Leon R., additional, Milinkovic, Ana, additional, O’Hara, Jessica, additional, Owen, David R., additional, Owens, Daniel, additional, Pacurar, Mihaela, additional, Rampling, Tommy, additional, Skene, Simon S., additional, Winston, Alan, additional, Woolley, James, additional, Yim, Yee Ting N., additional, Dunn, David T., additional, McCormack, Sheena, additional, and Shattock, Robin John, additional

Published
2022
Full Text
View/download PDF

33. The association between hepatitis B virus infection and nonliver malignancies in persons living with HIV: results from the EuroSIDA study

Author

Mocroft, Amanda, Miro, Jose M., Wandeler, Gilles, Llibre, Josep M., Boyd, Anders, van Bremen, Kathrin, Beniowski, Marek, Mikhalik, Julia, Cavassini, Matthias, Maltez, Fernando, Duvivier, Claudine, Uberti Foppa, Caterina, Knysz, Brygida, Bakowska, Elzbieta, Kuzovatova, Elena, Domingo, Pere, Zagalo, Alexandra, Viard, Jean Paul, Degen, Olaf, Milinkovic, Ana, Benfield, Thomas, Peters, Lars, Harxhi, A., Losso, M., Kundro, M., Schmied, B., Zangerle, R., Karpov, I., Vassilenko, A., Mitsura, V. M., Paduto, D., Clumeck, N., De Wit, S., Delforge, M., Florence, E., Vandekerckhove, L., Hadziosmanovic, V., Begovac, J., Machala, L., Sedlacek, D., Kronborg, G., Gerstoft, J., Katzenstein, T., Pedersen, C., Johansen, I. S., Ostergaard, L., Wiese, L., Moller, N. F., Nielsen, L. N., Zilmer, K., Smidt, J., Aho, I., Lacombe, K., Pradier, C., Fontas, E., Rockstroh, J., Behrens, G., Hoffmann, C., Stellbrink, H. J., Stefan, C., Bogner, J., Fätkenheuer, G., Chkhartishvili, N., Sambatakou, H., Adamis, G., Paissios, N., Szlávik, J., Gottfredsson, M., Devitt, E., Tau, L., Turner, D., Burke, M., Shahar, E., Wattad, L. M., Elinav, H., Haouzi, M., Elbirt, D., D’Arminio Monforte, A., Esposito, R., Mazeu, I., Mussini, C., Mazzotta, F., Gabbuti, A., Lazzarin, A., Castagna, A., Gianotti, N., Galli, M., Ridolfo, A., Uzdaviniene, V., Matulionyte, R., Staub, T., Hemmer, R., Dragas, S., Stevanovic, M., vd Valk, M., Trajanovska, J., Reikvam, D. H., Maeland, A., Bruun, J., Szetela, B., Inglot, M., Flisiak, R., Grzeszczuk, A., Parczewski, M., Maciejewska, K., Aksak-Was, B., Mularska, E., Jablonowska, E., Kamerys, J., Wojcik, K., Mozer-Lisewska, I., Rozplochowski, B., Mansinho, K., Radoi, R., Oprea, C., Gusev, D., Trofimova, T., Khromova, I., Borodulina, E., Ranin, J., Tomazic, J., Miró, J. M., Laguno, M., Martinez, E., Garcia, F., Blanco, J. L., Martinez-Rebollar, M., Mallolas, J., Callau, P., Rojas, J., Inciarta, A., Moreno, S., del Campo, S., Clotet, B., Jou, A., Paredes, R., Puig, J., Santos, J. R., Gutierrez, M., Mateo, G., Sambeat, M. A., Laporte, J. M., Svedhem, V., Thalme, A., Sönnerborg, A., Brännström, J., Flamholc, L., Kusejko, K., Braun, D., Calmy, A., Furrer, H., Battegay, M., Schmid, P., Kuznetsova, A., Sluzhynska, M., Johnson, M. A., Simons, E., Edwards, S., Phillips, A., Orkin, C., Winston, A., Clarke, A., Leen, C., Lundgren, J., Rasmussen, L. D., Kowalska, J. D., Guaraldi, G., Larsen, J. F., Bojesen, A., Neesgaard, B., Jaschinski, N., Fursa, O., Sather, M., Raben, D., Hansen, E. V., Kristensen, D., Fischer, A. H., Jensen, S. K., Elsing, T. W., Reekie, J., Cozzi-Lepri, A., Amele, S., Pelchen-Matthews, A., Roen, A., Tusch, E. S., Bannister, W., Mocroft, A., Miro, J. M., Wandeler, G., Llibre, J. M., Boyd, A., van Bremen, K., Beniowski, M., Mikhalik, J., Cavassini, M., Maltez, F., Duvivier, C., Uberti Foppa, C., Knysz, B., Bakowska, E., Kuzovatova, E., Domingo, P., Zagalo, A., Viard, J. -P., Degen, O., Milinkovic, A., Benfield, T., Peters, L., Harxhi, A., Losso, M., Kundro, M., Schmied, B., Zangerle, R., Karpov, I., Vassilenko, A., Mitsura, V. M., Paduto, D., Clumeck, N., De Wit, S., Delforge, M., Florence, E., Vandekerckhove, L., Hadziosmanovic, V., Begovac, J., Machala, L., Sedlacek, D., Kronborg, G., Gerstoft, J., Katzenstein, T., Pedersen, C., Johansen, I. S., Ostergaard, L., Wiese, L., Moller, N. F., Nielsen, L. N., Zilmer, K., Smidt, J., Aho, I., Lacombe, K., Pradier, C., Fontas, E., Rockstroh, J., Behrens, G., Hoffmann, C., Stellbrink, H. J., Stefan, C., Bogner, J., Fatkenheuer, G., Chkhartishvili, N., Sambatakou, H., Adamis, G., Paissios, N., Szlavik, J., Gottfredsson, M., Devitt, E., Tau, L., Turner, D., Burke, M., Shahar, E., Wattad, L. M., Elinav, H., Haouzi, M., Elbirt, D., D'Arminio Monforte, A., Esposito, R., Mazeu, I., Mussini, C., Mazzotta, F., Gabbuti, A., Lazzarin, A., Castagna, A., Gianotti, N., Galli, M., Ridolfo, A., Uzdaviniene, V., Matulionyte, R., Staub, T., Hemmer, R., Dragas, S., Stevanovic, M., vd Valk, M., Trajanovska, J., Reikvam, D. H., Maeland, A., Bruun, J., Szetela, B., Inglot, M., Flisiak, R., Grzeszczuk, A., Parczewski, M., Maciejewska, K., Aksak-Was, B., Mularska, E., Jablonowska, E., Kamerys, J., Wojcik, K., Mozer-Lisewska, I., Rozplochowski, B., Mansinho, K., Radoi, R., Oprea, C., Gusev, D., Trofimova, T., Khromova, I., Borodulina, E., Ranin, J., Tomazic, J., Laguno, M., Martinez, E., Garcia, F., Blanco, J. L., Martinez-Rebollar, M., Mallolas, J., Callau, P., Rojas, J., Inciarta, A., Moreno, S., del Campo, S., Clotet, B., Jou, A., Paredes, R., Puig, J., Santos, J. R., Gutierrez, M., Mateo, G., Sambeat, M. A., Laporte, J. M., Svedhem, V., Thalme, A., Sonnerborg, A., Brannstrom, J., Flamholc, L., Kusejko, K., Braun, D., Calmy, A., Furrer, H., Battegay, M., Schmid, P., Kuznetsova, A., Sluzhynska, M., Johnson, A. M., Simons, E., Edwards, S., Phillips, A., Johnson, M. A., Orkin, C., Winston, A., Clarke, A., Leen, C., Lundgren, J., Rasmussen, L. D., Kowalska, J. D., Guaraldi, G., Larsen, J. F., Bojesen, A., Neesgaard, B., Jaschinski, N., Fursa, O., Sather, M., Raben, D., Hansen, E. V., Kristensen, D., Fischer, A. H., Jensen, S. K., Elsing, T. W., Reekie, J., Cozzi-Lepri, A., Amele, S., Pelchen-Matthews, A., Roen, A., Tusch, E. S., Bannister, W., and Infectious diseases

Subjects
Hepatitis B virus, Hepatitis B Surface Antigens, Health Policy, virus diseases, HIV Infections, Hepatitis B, digestive system diseases, HBV DNA, hepatitis B, nonliver cancer, Infectious Diseases, Hepatitis B, Chronic, Neoplasms, DNA, Viral, Humans, Pharmacology (medical), 610 Medicine & health
Abstract

Objectives: The aim of this study was to assess the impact of hepatitis B virus (HBV) infection on non-liver malignancies in people living with HIV (PLWH). Methods: All persons aged ≥18 years with known hepatitis B virus (HBV) surface antigen (HBsAg) status after the latest of 1January 2001 and enrolment in the EuroSIDA cohort (baseline) were included in the study; persons were categorized as HBV positive or negative using the latest HBsAg test and followed to their first diagnosis of nonliver malignancy or their last visit. Results: Of 17485 PLWH included in the study, 1269 (7.2%) were HBV positive at baseline. During 151766 person-years of follow-up (PYFU), there were 1298 nonliver malignancies, 1199 in those currently HBV negative [incidence rate (IR)8.42/1000 PYFU; 95% confidence interval (CI) 7.94–8.90/1000 PYFU] and 99 in those HBV positive (IR10.54/1000 PYFU; 95% CI8.47–12.62/1000 PYFU). After adjustment for baseline confounders, there was a significantly increased incidence of nonliver malignancies in HBV-positive versus HBV-negative individuals [adjusted incidence rate ratio (aIRR)1.23; 95% CI 1.00–1.51]. Compared to HBV-negative individuals, HBsAg-positive/HBV-DNA-positive individuals had significantly increased incidences of nonliver malignancies (aIRR 1.37; 95% CI 1.00–1.89) and NHL (aIRR 2.57; 95% CI 1.16–5.68). There was no significant association between HBV and lung or anal cancer. Conclusions: We found increased rates of nonliver malignancies in HBsAg-positive participants, the increases being most pronounced in those who were HBV DNA positive and for NHL. If confirmed, these results may have implications for increased cancer screening in HIV-positive subjects with chronic HBV infection.

Published
2021

35. FRAX assessment in people ageing with HIV

Author

Mazzitelli, Maria, primary, Branca Isabel, Pereira, additional, Muramatsu, Takashi, additional, Chirwa, Mimie, additional, Mandalia, Sundhiya, additional, Moyle, Graeme, additional, Marta, Boffito, additional, and Milinkovic, Ana, additional

Published
2021
Full Text
View/download PDF

36. A phase IV, open-label three-arm study investigating the impact of a combination of tenofovir disoproxil fumarate/emtricitabine with raltegravir or dolutegravir or elvitegravir/cobicistat on renal function in HIV-1 antiretroviral naïve patients

Author

Bracchi, Margherita, primary, Pagani, Nicole, additional, Dalla Pria, Alessia, additional, Milinkovic, Ana, additional, Nwokolo, Nneka, additional, Thomas, Lervina, additional, Mandalia, Sundhyia, additional, Boffito, Marta, additional, and Moyle, Graeme, additional

Published
2021
Full Text
View/download PDF

38. HCV reinfection after HCV therapy among HIV/HCV���coinfected individuals in Europe

Author

Amele, Sarah, Sandri, Anastasia Karachalia, Rodger, Alison, Vandekerckhove, Linos, Benfield, Thomas, Milinkovic, Ana, Duvivier, Claudine, Stellbrink, Hans���J��rgen, Sambatakou, Helen, Chkhartishvili, Nikoloz, Caldeira, Luis, Laguno, Monserrat, Domingo, Pere, Wandeler, Gilles, Gisinger, Martin, Kuzovatova, Elena, Dragovic, Gordana, Knysz, Brygida, Matulionyte, Raimonda, Rockstroh, J��rgen Kurt, Lundgren, Jens Dilling, Mocroft, Amanda, and Peters, Lars

Subjects
610 Medicine & health
Published
2021
Full Text
View/download PDF

39. Switching from boosted PIs to dolutegravir decreases soluble CD14 and adiponectin in high cardiovascular risk people living with HIV

Author

Assoumou, Lambert, Moyle, Graeme, Waters, Laura, Johnson, Margaret, Domingo, Pere, Fox, Julie, Stellbrink, Hans-Jürgen, Guaraldi, Giovanni, Masiá, Mar, Gompels, Mark, De Wit, Stephane, Florence, Eric, Esser, Stefan, Raffi, François, Behrens, Georg, Pozniak, Anton, Gatell, José M., Martínez, Esteban, Vandekerckhove, Linos, Caluwé, Els, Necsoi, Coca, Van Frankenhuijsen, Maartje, Allavena, Clotilde, Reliquet, Véronique, Boutoille, David, Cavellec, Morane, André-Garnier, Elisabeth, Rodallec, Audrey, Le Tourneau, Thierry, Connault, Jérôme, Molina, Jean-Michel, Ferret, Samuel, Previlon, Miresta, Yazdanpanah, Yazdan, Landman, Roland, Joly, Véronique, Pinto, Adriana, Katlama, Christine, Caby, Fabienne, Ktorza, Nadine, Schneider, Luminita, Stephan, Christoph, Wolf, Timo, Schüttfort, Gundolf, Rockstroh, Juergen, Wasmuth, Jan-Christian, Schwarze-Zander, Carolynne, Boesecke, Christoph, Stellbrink, Hans-Jurgen, Hoffmann, Christian, Sabranski, Michael, Jablonka, Robert, Wiehler, Heidi, Stoll, Matthias, Ahrenstorf, Gerrit, Nardini, Giulia, Beghetto, Barbara, Montforte, Antonella D'Arminio, Bini, Teresa, Cogliandro, Viola, Di Pietro, Massimo, Fusco, Francesco Maria, Galli, Massimo, Rusconi, Stefano, Giacomelli, Andrea, Meraviglia, Paola, Martinez, Esteban, González-Cordón, Ana, Gatell, José Maria, Torres, Berta, Mateo, Gracia, Gutierrez, Mar, Portilla, Joaquin, Merino, Esperanza, Reus, Sergio, Boix, Vicente, Masia, Mar, Gutiérrez, Félix, Padilla, Sergio, Clotet, Bonaventura, Negredo, Eugenia, Bonjoch, Anna, Casado, José L, Bañón-Escandell, Sara, Saban, Jose, Duque, Africa, Podzamczer, Daniel, Saumoy, Maria, Acerete, Laura, Gonzalez-Garcia, Juan, Bernardino, José Ignacio, Arribas, José Ramón, Hontañón, Victor, Pagani, Nicole, Bracchi, Margherita, Vera, Jaime, Clarke, Amanda, Adams, Tanya, Richardson, Celia, Winston, Alan, Mora-Peris, Borja, Mullaney, Scott, De Esteban, Nahum, Milinkovic, Ana, Pett, Sarah, Tiraboschi, Juan Manuel, Youle, Mike, Orkin, Chloe, Rackstraw, Simon, Hand, James, Jennings, Louise, Nicholls, Jane, Johnston, Sarah, and NEAT022 Study Grp

Subjects
Microbiology (medical), medicine.medical_specialty, Pyridones, Lipopolysaccharide Receptors, Medizin, HIV Infections, Inflammation, Piperazines, chemistry.chemical_compound, Insulin resistance, Risk Factors, Internal medicine, Oxazines, medicine, Humans, Pharmacology (medical), Endothelial dysfunction, Biology, Pharmacology, Ritonavir, biology, Adiponectin, business.industry, Pharmacology. Therapy, C-reactive protein, medicine.disease, Infectious Diseases, Endocrinology, chemistry, Cardiovascular Diseases, Heart Disease Risk Factors, Heart failure, Dolutegravir, biology.protein, Human medicine, medicine.symptom, business, Heterocyclic Compounds, 3-Ring, Weight gain
Abstract

Background Switching from boosted PIs to dolutegravir in people living with HIV (PLWH) with high cardiovascular risk improved plasma lipids at 48 weeks in the NEAT022 trial. Whether this strategy may have an impact on cardiovascular biomarkers is unknown. Methods We assessed 48 week changes in biomarkers associated with inflammation, endothelial dysfunction, monocyte immune activation, oxidation, insulin resistance, hypercoagulability, heart failure, myocardial injury, and glomerular and tubular kidney injury. Results Of 415 PLWH randomized in the NEAT022 study, 313 (75.4%) remained on allocated therapy and had paired samples available. Soluble CD14 (–11%, P Conclusions Switching from boosted PIs to dolutegravir in PLWH with high cardiovascular risk led to soluble CD14 and adiponectin reductions at 48 weeks. While decreasing soluble CD14 may entail favourable health effects in PLWH, adiponectin reduction may reflect less insulin sensitivity associated with weight gain.

Published
2021

40. HCV reinfection after HCV therapy among HIV/HCV‐coinfected individuals in Europe.

Author

Amele, Sarah, Sandri, Anastasia Karachalia, Rodger, Alison, Vandekerckhove, Linos, Benfield, Thomas, Milinkovic, Ana, Duvivier, Claudine, Stellbrink, Hans‐Jürgen, Sambatakou, Helen, Chkhartishvili, Nikoloz, Caldeira, Luis, Laguno, Monserrat, Domingo, Pere, Wandeler, Gilles, Gisinger, Martin, Kuzovatova, Elena, Dragovic, Gordana, Knysz, Brygida, Matulionyte, Raimonda, and Rockstroh, Jürgen Kurt

Subjects
HIV infection transmission, HEPATITIS C diagnosis, HIV infections, CONFIDENCE intervals, HEPATITIS C, REINFECTION, ANTIVIRAL agents, RNA, INTERFERONS, RESEARCH funding, ODDS ratio, LONGITUDINAL method
Abstract

Objectives: Although direct‐acting antivirals (DAAs) can clear HCV in nearly all HIV/HCV‐coinfected individuals, high rates of reinfection may hamper efforts to eliminate HCV in this population. We investigated reinfection after sustained virological response (SVR) in HIV/HCV‐coinfected individuals in Europe. Methods: Factors associated with odds of reinfection by 2 years after SVR in EuroSIDA participants with one or more HCV‐RNA test and 2 years follow‐up were assessed using logistic regression. Results: Overall, 1022 individuals were included. The median age was 50 (interquartile range: 43–54 years), and most were male (78%), injection drug users (52%), and received interferon (IFN)‐free DAAs (62%). By 24 months, 75 [7.3%, 95% confidence interval (CI): 5.7–8.9%] individuals were reinfected. Among individuals treated prior to 2014, 16.1% were reinfected compared with 4.2% and 8.3%, respectively, among those treated during or after 2014 with IFN‐free and IFN‐based therapy. After adjustment, individuals who had started treatment during or after 2014 with IFN‐free or IFN‐based therapy had significantly lower odds of reinfection (adjusted odds ratio = 0.21, 95% CI: 0.11–0.38; 0.43, 95% CI: 0.22–0.83) compared with those who had received therapy before 2014. There were no significant differences in odds of reinfection according to age, gender, European region, HIV transmission risk group or liver fibrosis. Conclusions: Among HIV/HCV‐coinfected individuals in Europe, 7.3% were reinfected with HCV within 24 months of achieving SVR, with evidence suggesting that this is decreasing over time and with use of newer HCV regimens. Harm reduction to reduce reinfection and surveillance to detect early reinfection with an offer of treatment are essential to eliminate HCV. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

41. The association between hepatitis B virus infection and nonliver malignancies in persons living with HIV: results from the EuroSIDA study.

Author

Mocroft, Amanda, Miro, Jose M., Wandeler, Gilles, Llibre, Josep M., Boyd, Anders, van Bremen, Kathrin, Beniowski, Marek, Mikhalik, Julia, Cavassini, Matthias, Maltez, Fernando, Duvivier, Claudine, Uberti Foppa, Caterina, Knysz, Brygida, Bakowska, Elzbieta, Kuzovatova, Elena, Domingo, Pere, Zagalo, Alexandra, Viard, Jean‐Paul, Degen, Olaf, and Milinkovic, Ana

Subjects
HEPATITIS B, HIV-positive persons, VIRAL antigens, RESEARCH, CONFIDENCE intervals, DNA, LUNG tumors, MATHEMATICAL variables, ANAL tumors, TUMORS, ODDS ratio, ANTIGENS
Abstract

Objectives: The aim of this study was to assess the impact of hepatitis B virus (HBV) infection on non‐liver malignancies in people living with HIV (PLWH). Methods: All persons aged ≥ 18 years with known hepatitis B virus (HBV) surface antigen (HBsAg) status after the latest of 1 January 2001 and enrolment in the EuroSIDA cohort (baseline) were included in the study; persons were categorized as HBV positive or negative using the latest HBsAg test and followed to their first diagnosis of nonliver malignancy or their last visit. Results: Of 17 485 PLWH included in the study, 1269 (7.2%) were HBV positive at baseline. During 151 766 person‐years of follow‐up (PYFU), there were 1298 nonliver malignancies, 1199 in those currently HBV negative [incidence rate (IR) 8.42/1000 PYFU; 95% confidence interval (CI) 7.94–8.90/1000 PYFU] and 99 in those HBV positive (IR 10.54/1000 PYFU; 95% CI 8.47–12.62/1000 PYFU). After adjustment for baseline confounders, there was a significantly increased incidence of nonliver malignancies in HBV‐positive versus HBV‐negative individuals [adjusted incidence rate ratio (aIRR) 1.23; 95% CI 1.00–1.51]. Compared to HBV‐negative individuals, HBsAg‐positive/HBV‐DNA‐positive individuals had significantly increased incidences of nonliver malignancies (aIRR 1.37; 95% CI 1.00–1.89) and NHL (aIRR 2.57; 95% CI 1.16–5.68). There was no significant association between HBV and lung or anal cancer. Conclusions: We found increased rates of nonliver malignancies in HBsAg‐positive participants, the increases being most pronounced in those who were HBV DNA positive and for NHL. If confirmed, these results may have implications for increased cancer screening in HIV‐positive subjects with chronic HBV infection. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

44. Safety and Immunogenicity of a Self-Amplifying RNA Vaccine Against COVID-19: COVAC1, a Phase I, Dose-Ranging Trial

Author

Pollock, Katrina M., primary, Cheeseman, Hannah M., additional, Szubert, Alexander J., additional, Libri, Vincenzo, additional, Boffito, Marta, additional, Owen, David, additional, Bern, Henry, additional, O’Hara, Jessica, additional, McFarlane, Leon R., additional, Lemm, Nana-Marie, additional, McKay, Paul F., additional, Rampling, Tommy, additional, Yim, Yee Ting N., additional, Milinkovic, Ana, additional, Kingsley, Cherry, additional, Cole, Tom, additional, Fagerbrink, Susanne, additional, Aban, Marites, additional, Tanaka, Maniola, additional, Mehdipour, Savviz, additional, Robbins, Alexander, additional, Budd, William, additional, Faust, Saul N., additional, Hassanin, Hana, additional, Cosgrove, Catherine A., additional, Winston, Alan, additional, Fidler, Sarah, additional, Dunn, David T., additional, McCormack, Sheena, additional, and Shattock, Robin John, additional

Published
2021
Full Text
View/download PDF

45. Gynecomastia among HIV-infected patients is associated with hypogonadism: a case-control study

Author

Biglia, Alejandra, Blanco, Jose L., Martinez, Esteban, Domingo, Pere, Casamitjana, Roser, Sambeat, Maria, Milinkovic, Ana, Garcia, Mercedes, Laguno, Montserrat, Leon, Agathe, Larrousse, Maria, Lonca, Montserrat, Mallolas, Josep, and Gatell, Jose M.

Subjects
Hypogonadism -- Risk factors, Hypogonadism -- Research, Gynecomastia -- Risk factors, Gynecomastia -- Research, Health, Health care industry
Published
2004

47. Factors associated with severe impact of lipodystrophy on the quality of life of patients infected with HIV-1

Author

Blanch, Jordi, Rousaud, Araceli, Martinez, Esteban, De Lazzari, Elisa, Milinkovic, Ana, Peri, Josep-Maria, Blanco, Jose-Luis, Jaen, Jesus, Navarro, Victor, Massana, Guillem, and Gatell, Josep-Maria

Subjects
Lipodystrophy -- Care and treatment, Lipodystrophy -- Research, HIV infection -- Care and treatment, HIV infection -- Research, Health, Health care industry
Published
2004

48. Risk of metabolic abnormalities in patients infected with HIV receiving antiretroviral therapy that contains lopinavir-ritonavir

Author

Martinez, Esteban, Domingo, Pere, Galindo, Maria J., Milinkovic, Ana, Arroyo, Juan A., Baldovi, Francisco, Larrousse, Maria, Leon, Agathe, de Lazzari, Elisa, and Gatell, Jose M.

Subjects
Ritonavir -- Health aspects, Hyperlipidemia -- Care and treatment, HIV infection -- Care and treatment, HIV infection -- Research, Blood sugar monitoring -- Research, Antiviral agents -- Health aspects, Antiviral agents -- Research, Health, Health care industry
Published
2004

49. Short Communication: Predictive Value of HIV-Related Versus Traditional Risk Factors for Coronary Atherosclerosis in People Aging with HIV.

Author

Pereira, Branca, Mazzitelli, Maria, Milinkovic, Ana, Moyle, Graeme, Mandalia, Sundhiya, Al-hussaini, Abtehale, and Boffito, Marta

Abstract

Cardiovascular disease (CVD) is an important cause of morbidity in people living with HIV (PLWH). We compared the predictive value of HIV-related and traditional CVD risk factors to assess which factors best predict the presence of subclinical coronary atherosclerosis in PLWH. This is a cross-sectional study in PLWH over 50 years of age who performed computed tomography coronary artery calcium (CAC) scoring between 2009 and 2019 at Chelsea and Westminster Hospital. The following outcomes were analyzed: CAC = 0 (no calcification), CAC >0 (any calcification), CAC >100 (moderate calcification), and CAC >400 (severe calcification). Univariate and multivariate logistic regression analyses were performed to assess predictors of coronary calcification. A total of 744 patients were included (mean age 56 ± 5.7 years, 94.8% male, 84% white). A CAC >0 was found in 392 (52.7%), CAC >100 in 90 (12.1%), and CAC >400 in 42 (5.6%) subjects. CAC >100 was strongly associated with hypertension [odds ratio, OR: 2.91, (95% confidence interval: 1.93–4.36), p < .001], dyslipidemia [2.71 (1.81–4.06), p < .001], and diabetes [2.53 (1.29–4.96), p = .01]. Regarding HIV-specific factors, a significant association was found with exposure (>6 years) to protease inhibitors [1.67 (1.06–2.61), p = .05], whereas exposure to tenofovir (>8 years) was negatively associated with CAC >100 [0.54 (0.30–0.98), p = .05]. Despite the high prevalence of hypertension (45.4%) only 21.5% were on antihypertensives, whereas only 29.2% of eligible candidates were receiving lipid-lowering drugs for primary prevention of CVD. Traditional cardiometabolic risk factors remain the strongest predictors of coronary atherosclerosis in PLWH as in the general population. These results underscore the importance of optimizing treatment of hypertension and promoting primary prevention strategies that may be underused in PLWH. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

50. FRAX assessment in people ageing with HIV.

Author

Mazzitelli, Maria, Branca Isabel, Pereira, Muramatsu, Takashi, Chirwa, Mimie, Mandalia, Sundhiya, Moyle, Graeme, Marta, Boffito, and Milinkovic, Ana

Subjects
OSTEOPOROSIS diagnosis, HIV-positive persons, HOSPITALS, STATISTICS, GLOMERULAR filtration rate, PREDICTIVE tests, PHOTON absorptiometry, CROSS-sectional method, MULTIPLE regression analysis, OSTEOPENIA, OSTEOPOROSIS, DESCRIPTIVE statistics, BODY mass index, LONGITUDINAL method, ALGORITHMS, DISEASE risk factors
Abstract

Objectives: Current British HIV Association (BHIVA) guidelines recommend the use of FRAX for the routine assessment of bone fracture risk in people living with HIV over 50 years of age every 3 years. Bone mineral density measurement with dual‐energy X‐ray absorptiometry (DXA) scan is recommended for those with increased fracture risk (FRAX major > 10%). Our objectives were to estimate the prevalence of and risk factors for osteoporosis in a population of PLWH aged > 50 years and assess the utility of FRAX in predicting the presence of DXA‐proven osteoporosis in this cohort. Methods: This was a cross‐sectional study of a cohort of PLWH aged > 50 years attending the Chelsea and Westminster Hospital and who had a DXA scan between January 2009 and December 2018. FRAX scores were calculated using the Sheffield algorithm. Multiple regression models and Cohen's kappa values were used to assess risk factors for osteoporosis and agreement between FRAX and DXA scan results, respectively. Results: In all, 744 patients were included (92.9% male, mean age 56 ± 5 years). The prevalence rates of osteoporosis (at DXA scans) and osteopenia were 12.2% and 63.7%, respectively. FRAX major was > 10% in only two patients, while 90/91 (98.9%) patients with osteoporosis had a normal FRAX score. The presence of osteoporosis was significantly associated with low body mass index and estimated glomerular filtration rate (p < 0.05). Conclusion: Our results indicate that FRAX scores did not predict the presence of osteoporosis in our population of PLWH over 50 years of age and therefore FRAX scores may not be the appropriate tool to define eligibility to perform DXA scans in PLWH. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results